{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:04:11Z","timestamp":1784714651218,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13555-024-01200-5","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T15:26:40Z","timestamp":1719934000000},"page":"2285-2296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations"],"prefix":"10.1007","volume":"14","author":[{"given":"Melinda J.","family":"Gooderham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tsianakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Kerkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"1","key":"1200_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Prim. 2018;4(1):1. https:\/\/doi.org\/10.1038\/s41572-018-0001-z.","journal-title":"Nat Rev Dis Prim"},{"issue":"5","key":"1200_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657\u201382. https:\/\/doi.org\/10.1111\/jdv.14891.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1200_CR3","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1104a145","volume":"11","author":"M Nogueira","year":"2021","unstructured":"Nogueira M, Torres T. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol Pract Concept. 2021;11(4):e2021145. https:\/\/doi.org\/10.5826\/dpc.1104a145.","journal-title":"Dermatol Pract Concept"},{"issue":"1","key":"1200_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155\u201372. https:\/\/doi.org\/10.1016\/j.jaci.2018.08.022.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"1200_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/2040622318773686","volume":"9","author":"LFM Ari\u00ebns","year":"2018","unstructured":"Ari\u00ebns LFM, Bakker DS, van der Schaft J, Garritsen FM, Thijs JL, de Bruin-Weller MS. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018;9(9):159\u201370. https:\/\/doi.org\/10.1177\/2040622318773686.","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"1200_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamadermatol.2021.4778","volume":"158","author":"B Strober","year":"2022","unstructured":"Strober B, Mallya UG, Yang M, et al. Treatment outcomes associated with dupilumab use in patients with atopic dermatitis: 1-year results from the RELIEVE-AD study. JAMA Dermatol. 2022;158(2):142\u201350. https:\/\/doi.org\/10.1001\/jamadermatol.2021.4778.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1200_CR7","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1080\/09546634.2021.1937485","volume":"33","author":"JAF Oosterhaven","year":"2022","unstructured":"Oosterhaven JAF, Spekhorst LS, Zhang J, et al. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab\u2014a cross-sectional study from the BioDay registry. J Dermatolog Treat. 2022;33(4):1986\u20139. https:\/\/doi.org\/10.1080\/09546634.2021.1937485.","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"1200_CR8","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s13555-023-00965-5","volume":"13","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Delevry D, Yang M, et al. Long-term effectiveness of dupilumab in patients with atopic dermatitis: results up to 3\u00a0years from the RELIEVE-AD study. Dermatol Ther (Heidelb). 2023;13(9):2107\u201320. https:\/\/doi.org\/10.1007\/s13555-023-00965-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1200_CR9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jdv.18170","volume":"36","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder S, Bhatia N, Gooderham MJ, et al. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. J Eur Acad Dermatol Venereol. 2022;36(8):1308\u201317. https:\/\/doi.org\/10.1111\/jdv.18170.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10290","key":"1200_CR10","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/s0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase\u00a03 trials. Lancet. 2021;397(10290):2151\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(21)00588-2.","journal-title":"Lancet"},{"issue":"2","key":"1200_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase\u00a0III trials. Br J Dermatol. 2020;183(2):242\u201355. https:\/\/doi.org\/10.1111\/bjd.18898.","journal-title":"Br J Dermatol"},{"key":"1200_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.682547","volume":"8","author":"M Le","year":"2021","unstructured":"Le M, Berman-Rosa M, Ghazawi FM, et al. Systematic review on the efficacy and safety of oral Janus kinase inhibitors for the treatment of atopic dermatitis. Front Med (Lausanne). 2021;8: 682547. https:\/\/doi.org\/10.3389\/fmed.2021.682547.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"1200_CR13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaad.2023.05.033","volume":"89","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Ladizinski B, Prajapati VH, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase\u00a03, randomized, controlled trial (Heads Up). J Am Acad Dermatol. 2023;89(3):478\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2023.05.033.","journal-title":"J Am Acad Dermatol"},{"issue":"10348","key":"1200_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase\u00a03 trial. Lancet. 2022;400(10348):273\u201382. https:\/\/doi.org\/10.1016\/s0140-6736(22)01199-0.","journal-title":"Lancet"},{"issue":"9","key":"1200_CR15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1200_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"issue":"1","key":"1200_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1):e002735. https:\/\/doi.org\/10.1136\/rmdopen-2022-002735.","journal-title":"RMD Open"},{"issue":"10","key":"1200_CR18","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1111\/jdv.19255","volume":"37","author":"A Wollenberg","year":"2023","unstructured":"Wollenberg A, Thyssen JP, Bieber T, Chan G, Kerkmann U. A detailed look at the European Medicines Agency\u2019s recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(10):2041\u20136. https:\/\/doi.org\/10.1111\/jdv.19255.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1200_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase\u00a0II and phase\u00a0III clinical trial program. Am J Clin Dermatol. 2021;22(5):693\u2013707. https:\/\/doi.org\/10.1007\/s40257-021-00618-3.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1200_CR20","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase\u00a02 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2855.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"1200_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase\u00a03 trial. Lancet. 2020;396(10246):255\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(20)30732-7.","journal-title":"Lancet"},{"issue":"8","key":"1200_CR22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1200_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2019380.","journal-title":"N Engl J Med"},{"issue":"1","key":"1200_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase\u00a03 trial. J Am Acad Dermatol. 2022;86(1):104\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.075.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1200_CR25","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165\u201373. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2830.","journal-title":"JAMA Dermatol"},{"issue":"1s","key":"1200_CR26","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1097\/der.0000000000000770","volume":"32","author":"BS Kim","year":"2021","unstructured":"Kim BS, Silverberg JI, St\u00e4nder S, et al. Rapid improvement of itch associated with atopic dermatitis with abrocitinib is partially independent of overall disease improvement: results from pooled phase\u00a02b and 3 monotherapy studies. Dermatitis. 2021;32(1s):S39\u201344. https:\/\/doi.org\/10.1097\/der.0000000000000770.","journal-title":"Dermatitis"},{"key":"1200_CR27","unstructured":"Cork MJ, Deleuran M, Geng B, et al. Abrocitinib treatment in patients with moderate-to-severe atopic dermatitis: safety of abrocitinib stratified by age. In: Presented at the European Academy of Dermatology and Venereology (EADV) \u2013 30th Congress; September 29\u2013October 2, Virtual. 2021."},{"key":"1200_CR28","doi-asserted-by":"crossref","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis with over 5000 patient-years of exposure. J Am Acad Dermatol. 2023;89(3). supplement AB58.","DOI":"10.1016\/j.jaad.2023.07.234"},{"issue":"10","key":"1200_CR29","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.19280","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, Silverberg JI, Papp KA, et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: results from phase\u00a03 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023;37(10):2056\u201366. https:\/\/doi.org\/10.1111\/jdv.19280.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1200_CR30","doi-asserted-by":"publisher","unstructured":"Paller AS, Cork MJ, Flohr C, et al. P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND. Br J Dermatol. 2023;188(Supplement_4):ljad113.09. https:\/\/doi.org\/10.1093\/bjd\/ljad113.109.","DOI":"10.1093\/bjd\/ljad113.109"},{"key":"1200_CR31","unstructured":"European Medicines Agency. Cibinqo\u00ae (abrocitinib). Summary of Product Characteristics (SmPC). Pfizer Europe MA EEIG: Belgium. 2024."},{"key":"1200_CR32","unstructured":"Cibinqo (abrocitinib) tablets, for oral use. Prescribing information. Pfizer Inc. 2023."},{"key":"1200_CR33","unstructured":"European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders [press release]. London, UK; 2023."},{"issue":"3","key":"1200_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13318-021-00745-6","volume":"47","author":"X Wang","year":"2022","unstructured":"Wang X, Dowty ME, Wouters A, et al. Assessment of the effects of inhibition or induction of CYP2C19 and CYP2C9 enzymes, or inhibition of OAT3, on the pharmacokinetics of abrocitinib and its metabolites in healthy individuals. Eur J Drug Metab Pharmacokinet. 2022;47(3):419\u201329. https:\/\/doi.org\/10.1007\/s13318-021-00745-6.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"10","key":"1200_CR35","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/jcph.1858","volume":"61","author":"EQ Wang","year":"2021","unstructured":"Wang EQ, Le V, O\u2019Gorman M, et al. Effects of hepatic impairment on the pharmacokinetics of abrocitinib and its metabolites. J Clin Pharmacol. 2021;61(10):1311\u201323. https:\/\/doi.org\/10.1002\/jcph.1858.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"1200_CR36","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1124\/dmd.122.000829","volume":"50","author":"JN Bauman","year":"2022","unstructured":"Bauman JN, Doran AC, King-Ahmad A, et al. The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective Janus kinase inhibitor, in humans. Drug Metab Dispos. 2022;50(8):1106\u201318. https:\/\/doi.org\/10.1124\/dmd.122.000829.","journal-title":"Drug Metab Dispos"},{"key":"1200_CR37","doi-asserted-by":"publisher","unstructured":"Bieber T, Katoh N, Simpson EL, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6\u00a0years and up to 3.9\u00a0years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat. 2023;34(1):2161812. https:\/\/doi.org\/10.1080\/09546634.2022.2161812.","DOI":"10.1080\/09546634.2022.2161812"},{"key":"1200_CR38","doi-asserted-by":"publisher","unstructured":"Stone J, Hangge P, Albadawi H, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther. 2017;7(Suppl 3):S276\u2013S284. https:\/\/doi.org\/10.21037\/cdt.2017.09.01.","DOI":"10.21037\/cdt.2017.09.01"},{"issue":"4","key":"1200_CR39","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.emc.2017.06.003","volume":"35","author":"M Olaf","year":"2017","unstructured":"Olaf M, Cooney R. Deep venous thrombosis. Emerg Med Clin North Am. 2017;35(4):743\u201370. https:\/\/doi.org\/10.1016\/j.emc.2017.06.003.","journal-title":"Emerg Med Clin North Am"},{"issue":"2","key":"1200_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1076029616683802","volume":"24","author":"A Gialeraki","year":"2018","unstructured":"Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M. Oral contraceptives and HRT risk of thrombosis. Clin Appl Thromb Hemost. 2018;24(2):217\u201325. https:\/\/doi.org\/10.1177\/1076029616683802.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"11","key":"1200_CR41","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1007\/s10067-021-05911-4","volume":"40","author":"S Mori","year":"2021","unstructured":"Mori S, Ogata F, Tsunoda R. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol. 2021;40(11):4457\u201371. https:\/\/doi.org\/10.1007\/s10067-021-05911-4.","journal-title":"Clin Rheumatol"},{"key":"1200_CR42","unstructured":"Thaci D, De Bruin\u2011weller M, Cork M, et al. Baseline use of oral contraceptives or hormone replacement therapy in patients with moderate-to-severe atopic dermatitis treated with abrocitinib in the phase\u00a02 and phase\u00a03 JADE clinical trial program and reported venous thromboembolic outcomes. In: Presented at the Annual European Academy of Dermatology and Venereology (EADV) Congress; October 11\u201314, Berlin, Germany. 2023."},{"key":"1200_CR43","doi-asserted-by":"crossref","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Safety of abrocitinib in 3582 patients with monderate-to-severe atopic dermatitis with over 900 patients exposed for almost 2\u00a0years. In: Presented at the 31st European Academy of Dermatology and Venereology (EADV) Hybrid Congress; September 7\u201310, Milan, Italy. 2022.","DOI":"10.1093\/bjd\/ljac140.025"},{"issue":"25","key":"1200_CR44","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/cir.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APHA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082\u2013143. https:\/\/doi.org\/10.1161\/cir.0000000000000625.","journal-title":"Circulation"},{"issue":"1","key":"1200_CR45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"1200_CR46","unstructured":"Tsoris A, Marlar CA. Use of the Child Pugh score in liver disease. Statpearls. Treasure Island (FL): StatPearls; 2022."},{"issue":"4","key":"1200_CR47","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/jcph.1980","volume":"62","author":"EQ Wang","year":"2022","unstructured":"Wang EQ, Le V, Winton JA, et al. Effects of renal impairment on the pharmacokinetics of abrocitinib and its metabolites. J Clin Pharmacol. 2022;62(4):505\u201319. https:\/\/doi.org\/10.1002\/jcph.1980.","journal-title":"J Clin Pharmacol"},{"key":"1200_CR48","unstructured":"US Food and Drug Administration. Shingrix. Prescribing Information. 2023. https:\/\/www.fda.gov\/media\/108597\/download"},{"key":"1200_CR49","doi-asserted-by":"publisher","unstructured":"Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm6703a5.","DOI":"10.15585\/mmwr.mm6703a5"},{"key":"1200_CR50","unstructured":"Cibinqo 100\u00a0mg film-coated tablets (summary of product characteristics). Pfizer; 2021."},{"issue":"5","key":"1200_CR51","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945\u201373.e33. https:\/\/doi.org\/10.1016\/j.jaad.2015.12.037.","journal-title":"J Am Acad Dermatol"},{"key":"1200_CR52","doi-asserted-by":"publisher","unstructured":"Richez C, Morel J, Cornec D, et al. Practical management of patients on Janus kinase inhibitor (JAKi) therapy: practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR). Jt Bone Spine. 2019;86(Suppl 1):eS2\u2013eS103. https:\/\/doi.org\/10.1016\/s1297-319x(19)30154-x.","DOI":"10.1016\/s1297-319x(19)30154-x"},{"issue":"1","key":"1200_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jdv.13957","volume":"31","author":"RN Werner","year":"2017","unstructured":"Werner RN, Nikkels AF, Marinovi\u0107 B, et al. European consensus-based (S2k) guideline on the management of herpes zoster\u2014guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 2: treatment. J Eur Acad Dermatol Venereol. 2017;31(1):20\u20139. https:\/\/doi.org\/10.1111\/jdv.13957.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1200_CR54","first-page":"612","volume":"85","author":"RL Gauer","year":"2012","unstructured":"Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician. 2012;85(6):612\u201322.","journal-title":"Am Fam Physician"},{"issue":"3","key":"1200_CR55","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select phase\u00a0III clinical programme. Ann Rheum Dis. 2020;80(3):304\u201311. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218510.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1200_CR56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40257-021-00602-x","volume":"22","author":"B King","year":"2021","unstructured":"King B, Maari C, Lain E, et al. Extended safety analysis of baricitinib 2\u00a0mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials. Am J Clin Dermatol. 2021;22(3):395\u2013405. https:\/\/doi.org\/10.1007\/s40257-021-00602-x.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1200_CR57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11926-010-0104-3","volume":"12","author":"R Valiyil","year":"2010","unstructured":"Valiyil R, Christopher-Stine L. Drug-related myopathies of which the clinician should be aware. Curr Rheumatol Rep. 2010;12(3):213\u201320. https:\/\/doi.org\/10.1007\/s11926-010-0104-3.","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"1200_CR58","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1373\/49.8.1331","volume":"49","author":"FS Apple","year":"2003","unstructured":"Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology\/American College of Cardiology Consensus Recommendations. Clin Chem. 2003;49(8):1331\u20136. https:\/\/doi.org\/10.1373\/49.8.1331.","journal-title":"Clin Chem"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01200-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01200-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01200-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T14:28:10Z","timestamp":1724077690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01200-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01200-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Melinda J. Gooderham has received grants, personal fees, honoraria, and\/or nonfinancial support from Pfizer Inc., AbbVie, Amgen, Akros Pharma, Arcutis, AnaptysBio, Aristea, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, InMagene, JAMP Pharma, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Moonlake, Meiji, Novartis, Roche, Sanofi Genzyme, Regeneron Pharmaceuticals, Sun Pharma, Takeda, Tarsus, UCB, Union and Ventyx. Marjolein de Bruin-Weller is a consultant, advisory board member, and\/or speaker for Pfizer Inc., AbbVie, Almirall, Arena, Aslan, Eli Lilly and Company, Galderma, Janssen, LEO Pharma, Regeneron Pharmaceuticals, and Sanofi Genzyme. Stephan Weidinger has received institutional research grants from Pfizer Inc., La Roche-Posay, LEO Pharma, and Sanofi Deutschland GmbH; has performed consultancies for Pfizer Inc., AbbVie, Almirall, Boehringer Ingelheim, Eli Lilly and Company, Galderma, Kymab, LEO Pharma, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme; has lectured at educational events sponsored by Pfizer Inc., AbbVie, Almirall, Galderma, LEO Pharma, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme; and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Michael J. Cork has been a clinical trial investigator for Pfizer Inc., Atopix, Galapagos, Hyphens, Johnson & Johnson, Kymab, LEO Pharma, L\u2019Oreal\/La Roche-Posay, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme; and an advisory board member, consultant, and\/or invited lecturer for Pfizer Inc., Abbvie, Amlar, Astellas, Atopix, Boots, Dermavant, Galapagos, Galderma, Hyphens, Johnson & Johnson, Kymab, LEO Pharma, L\u2019Oreal\/La Roche-Posay, Menlo Therapeutics, Novartis, Oxagen, Procter & Gamble, Reckitt Benckiser, Regeneron Pharmaceuticals, and Sanofi Genzyme. Lawrence F. Eichenfield has served as a scientific adviser, consultant, and\/or clinical study investigator for Pfizer Inc., AbbVie, Amgen, Apogee, Arcutis, Aslan, Attovia, Bristol Myers Squibb, Castle Biosciences, Dermavant, Eli Lilly and Company, Forte, Galderma, Incyte, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Regeneron Pharmaceuticals, Sanofi Genzyme, Target RWE and UCB. Eric L. Simpson has received grants from Pfizer Inc., Eli Lilly and Company, Kyowa Kirin, LEO Pharma, Merck, and Regeneron Pharmaceuticals, and personal fees from Pfizer Inc., Bausch Health (Valeant), Dermira, Eli Lilly and Company, Galderma, LEO Pharma, Menlo Therapeutics, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme. Athanasios Tsianakas has acted as a clinical investigator and received honoraria for lectures and consulting from Pfizer Inc. Claire Feeney is an employee and shareholder of Pfizer Inc. Urs Kerkmann was an employee and shareholder of Pfizer Pharma GmbH at the time the study was conducted. William Romero was an employee and shareholder of Pfizer Inc. at the time the study was conducted. He is currently an employee of Eli Lilly and Company Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}